News releases - Merck.com
WEB6 days ago · August 29, 2024. Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials. August 27, 2024. Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia. August 26, 2024.
Merck's Keytruda Secures First FDA-Approval For Rare Form …
WEB5 days ago · Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
WEB4 days ago · Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...
What can we help you find? - Merck
WEB3 days ago · This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject ...
Merck wins first FDA approval for Keytruda as a treatment for ...
WEB5 days ago · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEBRAHWAY, N.J., September 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYNOTE-006 ...
News & Stories - Merck
WEBSep 12, 2024 · Check out the latest Merck news and stories! Learn more about the leading science and technology company here.
FDA approves Merck's drug for rare, deadly lung condition
WEBMar 26, 2024 · The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients...
Merck Enters Two Strategic Collaborations to Strengthen AI …
WEBSep 20, 2023 · Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.
Merck Announces Second-Quarter 2024 Financial Results
WEBJul 30, 2024 · Full-Year 2024 Financial Outlook. Raises and Narrows Expected Worldwide Sales Range To Be Between $63.4 Billion and $64.4 Billion. Now Expects Non-GAAP EPS To Be Between $7.94 and $8.04; Outlook Reflects Negative Impact From One-Time Charge of Approximately $1.3 Billion, or $0.51 per Share, for the Acquisition of EyeBio.